3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
900
Lymphoma, Non-Hodgkin
685
Leukemia, Lymphocytic, Chronic, B-Cell
665
Lymphoma, Large B-Cell, Diffuse
617
Precursor Cell Lymphoblastic Leukemia-Lymphoma
605
Lymphoma, Follicular
516
Hodgkin Disease
442
Lymphoma, Mantle-Cell
421
Leukemia
410
Lymphoma, B-Cell, Marginal Zone
289
Burkitt Lymphoma
285
Recurrence
277
Leukemia, Myeloid, Acute
276
Multiple Myeloma
250
Myelodysplastic Syndromes
237
Waldenstrom Macroglobulinemia
187
Lymphoma, B-Cell
179
Lymphoma, Large-Cell, Immunoblastic
153
Lymphoma, T-Cell, Cutaneous
143
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
127
Lymphoma, T-Cell, Peripheral
123
Mycosis Fungoides
118
Myeloproliferative Disorders
112
Lymphoma, Large-Cell, Anaplastic
107
Dendritic Cell Sarcoma, Interdigitating
103
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
102
Neoplasms
98
Lymphoma, Extranodal NK-T-Cell
96
Hematologic Neoplasms
96
Sezary Syndrome
94
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Diffuse Large B-Cell Lymphoma Refractory
×
Lymphoid
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA